funded by @lbg.ac.at
Focusing on disease-driving mechanisms in patients with #PortalHypertension
#LiverFibrosis
UP next is WP5 introduced and led by
@mathiasjachs.bsky.social
🖐️
Developing prognostic #NIT models for #ACLD or #PSVD
📷More info in the video below 📷
UP next is WP5 introduced and led by
@mathiasjachs.bsky.social
🖐️
Developing prognostic #NIT models for #ACLD or #PSVD
📷More info in the video below 📷
Next one is MOTION WP 4 led and introduced by
@mattiasmandorfer.bsky.social
- Comparing #HVPG responses of our medication within our clinical trials to NSBBS...
🌐More info in the video below 📷🔽
Next one is MOTION WP 4 led and introduced by
@mattiasmandorfer.bsky.social
- Comparing #HVPG responses of our medication within our clinical trials to NSBBS...
🌐More info in the video below 📷🔽
WP lead Dr. Georg Semmler gives a quick introduction into how we’re tackling PSVD—from molecular insights to clinical impact. 💡
Watch now & learn more about our mission in hepatology!
#WP3 #LiverResearch #PSVD #ScienceInMotion
WP lead Dr. Georg Semmler gives a quick introduction into how we’re tackling PSVD—from molecular insights to clinical impact. 💡
Watch now & learn more about our mission in hepatology!
#WP3 #LiverResearch #PSVD #ScienceInMotion
In this particular WP the team is focusing on decompensated cirrhosis..
#liver #PortalHypertension #clinicaltrails #dACLD
🔽 Find out more in the video below 📷🔽
In this particular WP the team is focusing on decompensated cirrhosis..
#liver #PortalHypertension #clinicaltrails #dACLD
🔽 Find out more in the video below 📷🔽
Introducing MOTION WP 1 - Focusing on pathophysiological mechanisms in compensated Patients with liver cirrhosis....
🌐More info in the video below 🌐 🔽🔽
Introducing MOTION WP 1 - Focusing on pathophysiological mechanisms in compensated Patients with liver cirrhosis....
🌐More info in the video below 🌐 🔽🔽